GLP-1 agonists and cardiovascular endpoints in obesity without diabetes

A recent meta-analysis found that the use of GLP-1 agonists by overweight or obese patients without diabetes resulted in a statistically significant reduction of the risk of cardiovascular endpoints, with a number needed to treat (NNT) of 44. These findings, however, mostly concern semaglutide. Common adverse effects of all GLP-1 agonists include an elevated risk of gastrointestinal and gallbladder-related symptoms. Based on this new evidence, when can which GLP-1 agonist be considered, to reduce the risk of cardiovascular endpoints in patients without diabetes mellitus?

Authors

Publication Details

Journal
Geneesmiddelenbulletin
Published
2025-01-01
DOI
https://doi.org/10.35351/gebu.2025.2.6
Primary Topic
Diet and metabolism studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

GLP-1 agonists and cardiovascular endpoints in obesity without diabetes

Jorrit‐Jan Verlaan
Geneesmiddelenbulletin
Diet and metabolism studies
article

GLP-1 agonists and cardiovascular endpoints in obesity without diabetes

Jorrit‐Jan Verlaan
article en

Abstract

A recent meta-analysis found that the use of GLP-1 agonists by overweight or obese patients without diabetes resulted in a statistically significant reduction of the risk of cardiovascular endpoints, with a number needed to treat (NNT) of 44. These findings, however, mostly concern semaglutide. Common adverse effects of all GLP-1 agonists include an elevated risk of gastrointestinal and gallbladder-related symptoms. Based on this new evidence, when can which GLP-1 agonist be considered, to reduce the risk of cardiovascular endpoints in patients without diabetes mellitus?

GeneesmiddelenbulletinVol. e2025.2.6(2)
Zero hunger
Openalex Percentile: Top 86%
Diet and metabolism studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

GLP-1 agonists and cardiovascular endpoints in obesity without diabetes — Jorrit‐Jan Verlaan · Geneesmiddelenbulletin (2025) | TGRS Research Map | TGRS